Janus Henderson Group PLC boosted its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 6.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 533,036 shares of the medical equipment provider’s stock after purchasing an additional 30,854 shares during the period. Janus Henderson Group PLC owned about 1.21% of ABIOMED worth $76,384,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of ABMD. Parametric Portfolio Associates LLC boosted its position in ABIOMED by 4.3% in the first quarter. Parametric Portfolio Associates LLC now owns 43,001 shares of the medical equipment provider’s stock worth $5,384,000 after purchasing an additional 1,789 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new position in ABIOMED in the first quarter worth $200,000. Envestnet Asset Management Inc. boosted its position in ABIOMED by 21.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,221 shares of the medical equipment provider’s stock worth $404,000 after purchasing an additional 558 shares during the last quarter. KBC Group NV purchased a new position in ABIOMED in the first quarter worth $388,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in ABIOMED in the first quarter worth $244,000. 89.69% of the stock is currently owned by institutional investors and hedge funds.
ABIOMED, Inc. (ABMD) opened at 172.39 on Thursday. ABIOMED, Inc. has a 52 week low of $95.14 and a 52 week high of $175.71. The company has a market capitalization of $7.60 billion, a price-to-earnings ratio of 100.81 and a beta of 0.27. The firm has a 50-day moving average price of $159.60 and a 200-day moving average price of $143.86.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.03. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The company had revenue of $132.47 million for the quarter, compared to analysts’ expectations of $130.83 million. During the same period in the previous year, the firm posted $0.29 earnings per share. The firm’s revenue for the quarter was up 28.6% on a year-over-year basis. Analysts anticipate that ABIOMED, Inc. will post $2.24 EPS for the current fiscal year.
In other ABIOMED news, COO David M. Weber sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the sale, the chief operating officer now directly owns 125,122 shares of the company’s stock, valued at $18,471,760.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Eric A. Md Rose sold 982 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $145.17, for a total value of $142,556.94. Following the sale, the director now directly owns 13,634 shares in the company, valued at $1,979,247.78. The disclosure for this sale can be found here. Insiders have sold 61,782 shares of company stock worth $9,513,610 over the last three months. 7.00% of the stock is currently owned by insiders.
ABMD has been the topic of several research analyst reports. BidaskClub cut ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 28th. Piper Jaffray Companies set a $145.00 price target on ABIOMED in a research report on Tuesday, July 4th. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Morgan Stanley reaffirmed an “equal weight” rating and set a $140.00 price target (up previously from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. Finally, Jefferies Group LLC upped their price target on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $173.25.
WARNING: “ABIOMED, Inc. (ABMD) Shares Bought by Janus Henderson Group PLC” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/10/12/abiomed-inc-abmd-shares-bought-by-janus-henderson-group-plc.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
What are top analysts saying about ABIOMED Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ABIOMED Inc. and related companies.